Tempus Ai, Inc.
A maker of AI-driven precision medicine tools, Tempus runs a platform that analyzes tumor samples and other health data to help doctors personalize cancer, hereditary, and neuropsychiatry care. Its Diagnostics line performs genomic tests, while Data & Applications sells anonymized health insights and trial-matching services to drugmakers. Founded in 2015 by Eric Lefkofsky, it takes its name from the Latin for "time" — a nod to giving patients more of it.
Granted 222.1K · Sold 3.24M
Granted 5.88M · Sold 6.41M
Sold 1.95M
Sold 1.34M
Granted 824.5K · Sold 370.6K
Granted 629.3K · Sold 670.6K
Granted 453.8K · Sold 223.1K
Granted 21.4K
Granted 451.9K · Sold 251.3K
Granted 13.6K · Sold 4.3K
Granted 502.7K · Sold 240.9K
Granted 131.4K · Sold 43.7K
Granted 96.4K · Sold 55.7K
Granted 46.4K · Sold 8.4K
Granted 21.4K
Granted 36.4K · Sold 5.0K
Granted 46.4K · Sold 15.7K
Granted 46.4K · Sold 20.5K
| Insider | Stake change | Holds now | Granted / vested | Bought | Sold |
|---|---|---|---|---|---|
| Lefkofsky Eric P +1 co-filer10% owner, CEO and Chairman, Director, 10% owner · 54 transactions | — | 56.83Mas of Feb 2025 | 222.1K | — | 3.24M |
| Lefkofsky Eric PCEO and Chairman, Director, 10% owner · 216 transactions | — | 46.86M | 5.88M | — | 6.41M |
| Keywell Kimberly Jo +1 co-filer10% owner · 3 transactions | — | 28.99Mas of Dec 2024 | — | — | 1.95M |
| Keywell Bradley A10% owner · 9 transactions | — | 15.22Mas of Jan 2025 | — | — | 1.34M |
| Fukushima RyanCEO, Data · 74 transactions | — | 609.9K | 824.5K | — | 370.6K |
| Leonsis TheodoreDirector · 14 transactions | — | 137.8K | 629.3K | — | 670.6K |
| Polovin AndrewEVP, Chief Legal Officer · 51 transactions | — | 128.2K | 453.8K | — | 223.1K |
| Barris Peter JDirector · 5 transactions | — | 121.4K | 21.4K | — | — |
| Rogers James WilliamChief Financial Officer · 45 transactions | — | 114.9K | 451.9K | — | 251.3K |
| Schoenherr Thomas EdwardCEO, Diagnostics · 3 transactions | — | 87.0K | 13.6K | — | 4.3K |
| Phelps ErikEVP, Chief Admin. Officer · 37 transactions | — | 85.5K | 502.7K | — | 240.9K |
| Bartolucci Ryan MChief Accounting Officer · 24 transactions | — | 74.0K | 131.4K | — | 43.7K |
| Gottlieb ScottDirector · 12 transactions | — | 40.7K | 96.4K | — | 55.7K |
| West NadjaDirector · 13 transactions | — | 38.0K | 46.4K | — | 8.4K |
| Belcher Eric DDirector · 4 transactions | — | 35.5K | 21.4K | — | — |
| Epstein David RDirector · 16 transactions | — | 31.5K | 36.4K | — | 5.0K |
| Frederick Wayne A.I.Director · 10 transactions | — | 30.7K | 46.4K | — | 15.7K |
| Doudna Jennifer ADirector · 18 transactions | — | 25.9K | 46.4K | — | 20.5K |
Select a row to see that insider’s individual transactions. Sum of the holdings confirmed in the 12 months before this insider's last filing. A Form 4 reports a holding per line — held directly, or through a named trust, partnership or foundation, and in each share class separately — never a person’s total. Lines not restated in that time are left out and shown apart: an active filer restates what they still hold, so a line they did not restate is more often an entity since renamed, whose shares a successor line reports too. An amber marker means some were left out.
Net open-market activity over the last 5 years: -14.86M shares. Grants, option exercises and tax withholding are excluded — they are compensation mechanics, not decisions to buy or sell.